Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. RaySearch Laboratories AB's accounts receivables for the quarter that ended in Jun. 2026 was kr202 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
RaySearch Laboratories AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 67.62.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. RaySearch Laboratories AB's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was kr-19.16.
RaySearch Laboratories AB Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
RaySearch Laboratories AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), RaySearch Laboratories AB's accounts receivable are only considered to be worth 75% of book value:
RaySearch Laboratories AB's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
RaySearch Laboratories AB Accounts Receivable Related Terms
RaySearch Laboratories AB Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Accounts Receivable Chart
What does a Accounts Receivable of kr202 Mil mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Accounts Receivable of kr202 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Accounts Receivable too high?
RaySearch Laboratories AB's current Accounts Receivable is kr202 Mil. Overall, RaySearch Laboratories AB has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Accounts Receivable compare to VEEV and BTSG?
RaySearch Laboratories AB's Accounts Receivable of kr202 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Healthcare Providers & Services company?
A good Accounts Receivable depends on the Healthcare Providers & Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Accounts Receivable is kr202 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Fairly Valued. The stock's GF Value™ is kr188.74, compared to a current price of kr184.65 — trading 2.2% below its estimated fair value. The current Accounts Receivable is kr202 Mil. RaySearch Laboratories AB's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Accounts Receivable is kr202 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued.
The current stock price of kr184.65 is trading 2.2% below its estimated GF Value™ of kr188.74.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for CHIX:RAYBS:
Accounts Receivable: kr202 Mil
GF Value™: kr188.74 vs. price of kr184.65 (2.2% below fair value)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
92GF Score
Get the complete analysis for CHIX:RAYBS
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
